Biogen has ducked out of a four-year-old collaboration with Karyopharm on a drug candidate for the neurodegenerative disease amyotrophic lateral sclerosis that could have been worth up to $217 ...

What happens when the world's biggest meat company starts branding itself as a climate saviour? The feeder of the world? You get JBS, a methane cooker mega-corporation that's making billions and ...

SAO PAULO (Reuters) -The U.S. financial regulator's approval last month of a proposal by the world's largest meatpacker JBS to list on the New York Stock Exchange is drawing strong criticism from ...

Biogen Inc. (BIIB) came out with quarterly earnings of $3.02 per share, missing the Zacks Consensus Estimate of $3.26 per share. This compares to earnings of $3.67 per share a year ago. These ...

Biogen Inc.’s chief executive officer said that the impact from US tariffs will be limited, as three-quarters of its product revenue comes from drugs made in the US. CEO Chris Viehbacher told analysts ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know. Biogen beat analysts’ revenue expectations by 1.8% last quarter ...

Meat producer JBS has had its New York Stock Exchange (NYSE) listing application approved by the US Securities and Exchange Commission (SEC). The firm, which is already listed on the Brazilian ...

Biogen Inc.'s earnings and share price have declined due to falling Multiple Sclerosis treatment revenue; new drugs and pipeline show promise but haven't offset losses yet. Biogen's Multiple ...

The world’s largest meat company, Brazil-based JBS, has sought a listing on the New York Stock Exchange for more than a decade, but the company, which has long been accused of links to illegal ...

Biogen BIIB will report first-quarter 2025 results on May 1, before market open. In the last reported quarter, the company's earnings beat expectations by 0.58%. The Zacks Consensus Estimate for ...